Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach

European Journal of Nuclear Medicine

Volumn 27, Issue 5, 2000, Pages 601-609

  Riva, P ^a   Franceschi, G ^a   Riva, N ^a   Casi, M ^a   Santimaria, M ^a   Adamo, M ^a  

^a BUFALINI HOSPITAL   (Italy)

Author keywords

Malignant gliomas; Monoclonal antibodies; Radioimmunotherapy; Radioiodine; Radioyttrium

Indexed keywords

ADULT; AGED; BRAIN REGION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; RADIOIMMUNOLOGY; RADIOSENSITIVITY; REVIEW; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; GLIOMA; HUMANS; NUCLEAR MEDICINE; RADIOIMMUNOTHERAPY;

EID: 0034064244     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050549     Document Type: Review

References (78)

1. Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998; 9: 109-116.
2. Fernandez PM, Brem S. Malignant brain tumors in the elderly. Clin Geriatr Med 1997; 13: 327-338.
3. Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre JY. Descriptive epidemiology of cerebral gliomas in France. Cancer 1997; 79: 1195-1202.
4. Fiorani L, Ferro S, Giovannini A, Palazzini A, Azzimondi G, D'Alessandro R. Mortality from primary malignant brain tumors in the Province of Bologna, Italy, 1986-1988. Acta Neurol Scand 1996; 93: 355-359.
5. Black PM Brain tumors. N Engl J Med 1991; 324: 1555-1564.
6. Evan G. Cancer - a matter of life and cell death. Int J Cancer 1997; 71: 709-711.
7. Kuroiwa T, Kajimoto Y, Ohta T. Comparison between operative findings on malignant glioma by a fluorescein surgical microscopy and histological findings. Neurol Res 1999; 21: 130-134.
8. Black P. Management of malignant glioma: role of surgery in relation to multimodality therapy. J Neurovirol 1998; 4: 227-236.
9. Harbaugh KS, Black PM. Strategies in the surgical management of malignant gliomas. Semin Surg Oncol 1998; 14: 26-33.
10. Rampling R. Modern aspects of radiation therapy for glial tumours of the brain. Forum (Genova) 1998; 8: 289-301.
11. Larson DA, Wara WM. Radiotherapy of primary malignant brain tumors. Semin Surg Oncol 1998; 14: 34-42.
12. Gregor A, Cull A. Radiotherapy for malignant glioma. BMJ 1996; 313: 1500-1501.
13. Kohshi K, Kinoshita Y, Imada H, Kunugita N, Abe H, Terashima H, Tokui N, Uemura S. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br J Cancer 1999; 80: 236-241.
14. Burnet NG, Taylor RE. Malignant cerebral glioma. Modern radiotherapy techniques are needed to spare normal brain tissue. BMJ 1997; 22: 900-901.
15. Puduvalli VK, Yung AWK. New frontiers in therapy of malignant gliomas. Forum (Genova) 1998; 8: 261-269.
16. Shafman TD, Loeffler JS. Novel radiation technologies for malignant gliomas. Curr Opin Oncol 1999; 11: 147-151.
17. Kim HK, Thornton AF, Greenberg HS, Page MA, Junck L, Sandler HM. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am J Clin Oncol 1997; 20: 358-363.
18. Alexander E 3rd, Loeffler JS. The role of radiosurgery for glial neoplasms. Neurosurg Clin North Am 1999; 10: 351-358.
19. Foote KD, Friedman WA, Buatti JM, Bova FJ, Meeks SA. Linear accelerator radiosurgery in brain tumor management. Neurosurg Clin North Am 1999; 10: 203-242.
20. Wheeler FJ, Nigg DW, Capala J, Watkins PR, Vroegindeweij C, Auterinen I, Seppala T, Bleuel D. Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics. Med Phys 1999; 26: 1237-1244.
21. Ortiz de Urbina D, Santos M, Garcia-Berrocal I, Bustos JC, Samblas J, Gutierrez-Diaz JA, Delgado JM, Donckaster G, Calvo FA. Intraoperative radiation therapy in malignant glioma: early clinical results. Neurol Res 1995; 17: 289-294.
22. Fujiwara T, Honma Y, Ogawa T, Irie K, Kuyama H, Nagao S, Takashima H, Hosokawa A, Ohkawa M, Tanabe M. Intraoperative radiotherapy for gliomas. J Neurooncol 1995; 23: 81-86.
23. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998; 14: 79-87.
24. Matsumoto K, Nakagawa T, Tada E, Furuta T, Hiraki Y, Ohmoto T. Effect of adjuvant iridium-192 brachytherapy on the survival of patients with malignant gliomas. J Clin Oncol 1998; 16: 2202-2212.
25. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, Masri L, Law RE, Weiss MH. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619-622.
26. Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 1998; 42: 433-440.
27. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 1998; 44: 691-695.
28. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 1999; 71: 167-170.
29. Schmidt F, Schuster M, Streffer J, Schabet M, Weller M. Topotecan-based combination chemotherapy for human malignant glioma. Anticancer Res 1999; 19: 1217-1221.
30. Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest 1999; 17: 264-272.
31. Mizumatsu S, Matsumoto K, Maeda Y, Tamiya T, Furuta T, Ohmoto T. A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas. Gan To Kagaku Ryoho 1998; 25: 2055-2060.
32. Hirano Y, Mineura K, Mizoi K, Tomura N. Therapeutic results of intra-arterial chemotherapy in patients with malignant glioma. Int J Oncol 1998; 13: 537-542.
33. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery 1995; 37: 1128-1145.
34. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41: 44-48.
35. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998; 89: 42-51.
36. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895-900.
37. Puumalainen AM, Vapalahti M, Yla-Herttuala S. Adv gene therapy for malignant glioma patients. Exp Med Biol 1998; 451: 505-509.
38. Sasaki M, Plate KH. Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol 1998; 9: 1155-1166.
39. Alvord EC Jr. Survival in malignant gliomas. J Neurosurg 1994; 80: 350-351.
40. Sharkey RM, Blumenthal RD, Goldenberg DM. Development of cancer radioimmunotherapy and its potential use as an adjuvant treatment. In: Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. London, New York: CRC Press; 1995: 101-114.
41. Miyamoto CT, Brady LW, Rackover MA, Emrich J, Class R, Bender H, Micaily B, Steplewski Z. The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Recent Results Cancer Res 1996; 141: 183-192.
42. Brady LW, Markoe AM, Woo DV, Amendola BE, Karlsson UL, Rackover MA, Koprowski H, Steplewski Z, Peyster RG. Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 1990; 24: 151-160.
43. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992; 22: 225-230.
44. Brady LW. A new treatment for high grade gliomas of the brain. Bull Mem Acad R Med Belg 1998; 153: 255-261.
45. Devys A, Kraeber-Bodèré F, Chatal JF. Biodistribution and pharmacokinetics of radiolabelled antibodies. In: Riva P, ed. Cancer radioimmunotherapy: present and future. London: Harwood Academic Publishers; 1999: 51-72.
46. Riva P, Franceschi G, Riva N, Casi M. Role of radioimmunotherapy in the treatment of CNS malignant glioma: the intralesional approach. In: Riva P, ed. Cancer radioimmunotherapy: present and future. London: Harwood Academic Publishers; 1999: 485-502.
47. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26: 348-357.
48. 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65: 94-101.
49. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL, Bombardieri E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995; 31: 686-690.
50. Kairemo KJ. Radioimmunotherapy of solid cancers: a review. Acta Oncol 1996; 35: 343-355.
51. Gupta RK, Hird V, Slevin ML, Riva P, Trope C, Bullimore JA, Newman H, Williams CJ, Bleheen NM, Maughan TS, Otrowski MJ, Delaloy B, Tennival J, Howell A, Epenetos AA. Treatment of ascitis and pleural effusions due to malignant disease using iodine-131 labelled tumor associated monoclonal antibodies. Tumor Targeting 1996; 2: 197-203.
52. Kemshead J. Intrathecal injection of radiolabelled monoclonal antibodies for the treatment of malignancies within the central nervous system. In: Riva P, ed. Cancer radioimmunotherapy: present and future. London: Harwood Academic Publishers; 1999: 469-484.
53. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999; 141: 295-305.
54. Hopkins K, Papanastassiou V, Zananiri FA, Kemshead JT. A model to estimate the dose to tumour following intracavity administration of radioimmunoconjugates to patients with malignant gliomas. Br J Radiol 1997; 70: 1152-1161.
55. Hopkins K, Papanastassiou V, Kemshead JT. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res 1996; 141: 159-175.
56. Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, Seccamani E, Lazzari S, Fagioli L, Franceschi G, Sarti G, Riva N, Natali PG, Zardi L, Scassellati GA. Treatment of intracranial human glioblastoma by direct intratumoral administration of I-131 labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer 1992; 51: 7-13.
57. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989; 49: 2807-2813.
58. Leprini A, Querzè G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol 1994; 2: 117-123.
59. Carnemolla B, Siri A, Borsi L, Zardi L. Tenascin in disease. In: Crossin KL, ed. Tenascin and counteradhesive molecules of the extracellular matrix. London: Harwood Academic Publishers; 1996: 89-108.
60. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993; 67: 144-151.
61. Hopkins K, Papanastassiou V, Kemshead JT. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res 1996; 141: 159-175.
62. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993; 67: 144-151.
63. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with sub-arachnoid communication: phase I trial results. Clin Cancer Res 1996; 2: 963-972.
64. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, Riva N, Casi M, Moscatelli G, Frattarelli M. Intralesional radioimmunotherapy of malingnant gliomas: an effective treatment in recurrent tumors. Cancer (Suppl) 1994; 73: 1076-1082.
65. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995; 34: 121-131.
66. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G, Guiducci G, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maeke HR. Loco-regional radioimmunotherapy of high grade malignant gliomas by using specific monoclonal antibodies labeled with Y-90. A phase I study. Clin Cancer Res (Suppl) 1999; 5: 3275s-3280s.
67. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 1996; 35: 373-379.
68. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998; 16: 2202-2212.
69. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, Giuliani G, Casi M. Effectiveness of local radioimmunotherapy of high grade malignant glioma with antitenascin monoclonal antibodies. Minerva Biotecnologica 1999; 10: 138-145.
70. Carapella CM, Ferraironi A, Mastrostefano R, Mottolese M, Raus L, Sciuto R, Tofani A, Benassi M, Occhipinti EM, Maini CL. Radioimmunotherapy (RIT) associated with cisplatin as a radiosensitizer in recurrent malignant glioma: preliminary experience. Asco Meeting, Atlanta 1999; May 15-18, abstract n.569.
71. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Neurol Med Chir 1997; 37: 891-899.
72. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995; 34: 121-131.
73. 131I. Comparison of the results obtained in recurrent and newly diagnosed tumours. Cancer Res (Suppl) 1995; 55: 5952s-5956s.
74. 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2 - a preliminary report. J Neurooncol 1995; 24: 109-122.
75. 131 anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities: results of a phase I trial. Asco Meeting, Atlanta 1999; May 15-18, abstract n.547.
76. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma. Phase I and II study. Acta Oncol 1999; 38: 351-359.
77. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Stat Assoc 1958; 53: 457-481.
78. 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999; 5: 1025-1033.